Mattern Pharmaceuticals AG, Urigen deal

Urigen terminated a 2007 deal for exclusive, worldwide rights to develop and commercialize Mattern's Nasobol intranasal testosterone to treat male hypogonadism. Urigen said it ended the deal to alloca...